See more : Pyramid AG (M3BK.DE) Income Statement Analysis – Financial Results
Complete financial analysis of PepGen Inc. (PEPG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PepGen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sentage Holdings Inc. (SNTG) Income Statement Analysis – Financial Results
- Lian Hwa Foods Corporation (1231.TW) Income Statement Analysis – Financial Results
- Tesco PLC (TCO0.DE) Income Statement Analysis – Financial Results
- China Score Inc. (CIAS) Income Statement Analysis – Financial Results
- Centrepoint Alliance Limited (CAF.AX) Income Statement Analysis – Financial Results
PepGen Inc. (PEPG)
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| Gross Profit | -1.18M | -493.00K | -178.00K | -110.00K | -106.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.94M | 54.08M | 19.00M | 1.02M | 620.00K |
| General & Administrative | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 627.37K |
| SG&A | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Other Expenses | 0.00 | 110.00K | -172.00K | -20.00K | 0.00 |
| Operating Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.25M |
| Cost & Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.35M |
| Interest Income | 6.40M | 2.79M | 0.00 | 8.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| EBITDA | -83.58M | -67.81M | -26.93M | -1.77M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.77M | -68.30M | -27.11M | -1.88M | -1.35M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 2.90M | -172.00K | -12.00K | 8.00K |
| Income Before Tax | -78.55M | -65.40M | -27.28M | -1.89M | -1.35M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 73.00K | 3.71M | -58.56K | -8.00K | 0.00 |
| Net Income | -78.63M | -69.10M | -27.28M | -1.88M | -1.35M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| EPS Diluted | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| Weighted Avg Shares Out | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
| Weighted Avg Shares Out (Dil) | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain...
Did PepGen Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- PEPG
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data...
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain...
ATTENTION PEPG SHAREHOLDERS: Investors who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data...
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain...
PepGen Inc. (PEPG) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data...
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)
The heavy selling pressure might have exhausted for PepGen (PEPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is...
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain...
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain...
PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments
PepGen Inc. achieved positive data from the phase 2 CONNECT1 study, using PGN-EDO51 for the treatment of exon 51 skipping DMD patients; higher 10 mg/kg dosing of drug data is expected in early 2025. The global Duchenne Muscular Dystrophy treatment...
Source: https://incomestatements.info
Category: Stock Reports